Senataxin helicase, the causal gene defect in ALS4, is a significant modifier of C9orf72 ALS G4C2 and arginine-containing dipeptide repeat toxicity.
Saved in:
| Title: | Senataxin helicase, the causal gene defect in ALS4, is a significant modifier of C9orf72 ALS G4C2 and arginine-containing dipeptide repeat toxicity. |
|---|---|
| Authors: | Bennett CL; Departments of Pathology, Laboratory Medicine, Neurology, and Biological Chemistry, UCI Center for Neurotherapeutics, University of California Irvine School of Medicine, Irvine, CA, 92697, USA.; Department of Neurology, Duke University School of Medicine, Durham, NC, 27710, USA., Dastidar S; Department of Neurology, Duke University School of Medicine, Durham, NC, 27710, USA.; Center for Molecular Neurosciences, Kasturba Medical College, Manipal, 576104, India., Arnold FJ; Departments of Pathology, Laboratory Medicine, Neurology, and Biological Chemistry, UCI Center for Neurotherapeutics, University of California Irvine School of Medicine, Irvine, CA, 92697, USA., McKinstry SU; Department of Neurology, Duke University School of Medicine, Durham, NC, 27710, USA., Stockford C; Departments of Pathology, Laboratory Medicine, Neurology, and Biological Chemistry, UCI Center for Neurotherapeutics, University of California Irvine School of Medicine, Irvine, CA, 92697, USA., Freibaum BD; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA., Sopher BL; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, 98195, USA., Wu M; Department of Pharmacology, University of California, San Diego, La Jolla, CA, 92093, USA., Seidner G; Department of Pharmacology, University of California, San Diego, La Jolla, CA, 92093, USA., Joiner W; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, 98195, USA., Taylor JP; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, 20815, USA., West RJH; Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, S10 2HQ, UK. r.j.west@sheffield.ac.uk.; Neuroscience Institute, University of Sheffield, Sheffield, S10 2TN, UK. r.j.west@sheffield.ac.uk., La Spada AR; Departments of Pathology, Laboratory Medicine, Neurology, and Biological Chemistry, UCI Center for Neurotherapeutics, University of California Irvine School of Medicine, Irvine, CA, 92697, USA. alaspada@uci.edu.; Department of Neurology, Duke University School of Medicine, Durham, NC, 27710, USA. alaspada@uci.edu.; Department of Neurobiology and Behavior, University of California Irvine School of Biosciences, Irvine, CA, 92697, USA. alaspada@uci.edu.; UCI Center for Neurotherapeutics, University of California Irvine, Irvine, CA, 92697, USA. alaspada@uci.edu. |
| Source: | Acta neuropathologica communications [Acta Neuropathol Commun] 2023 Oct 17; Vol. 11 (1), pp. 164. Date of Electronic Publication: 2023 Oct 17. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101610673 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-5960 (Electronic) Linking ISSN: 20515960 NLM ISO Abbreviation: Acta Neuropathol Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2051-5960 |
|---|---|
| DOI: | 10.1186/s40478-023-01665-z |
